TAIPEI (Taiwan News) — A study conducted by National Taiwan University Hospital has uncovered a link between hepatitis B, ...

Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical studyFunding expected to extend cash runway into the second half of ...

Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...

The UK government has announced that it is renewing funding for the public health campaign HIV Prevention England for another year as part of efforts to end HIV transmission by 2030. The programme, ...

SOUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ:ALGS), a company specializing in therapies for liver and viral diseases with a current market capitalization of $96.58 million, announced today ...

Bluejay’s lead product candidate brelovitug (BJT-778) recently received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of chronic hepatitis delta (CHD).

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is ...

The Senate voted 53-47 to end debate on Robert F. Kennedy Jr.’s nomination, following public statements of support from some ...

StockNews.com lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a hold rating to a sell rating in a ...

We recently published a list of 10 Best Nasdaq Stocks Under $5 to Buy. In this article, we are going to take a look at where Arbutus Biopharma Corp.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.